Urinary proteome pattern in children with renal Fanconi syndrome

Nephrology Dialysis Transplantation

Volumn 24, Issue 7, 2009, Pages 2161-2169

  Drube, Jens ^a   Schiffer, Eric ^b   Mischak, Harald ^b   Kemper, Markus J ^c   Neuhaus, Thomas ^d   Pape, Lars ^a   Lichtinghagen, Ralf ^a   Ehrich, Jochen H H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Capillary electrophoresis; DeToni Debr Fanconi syndrome; Mass spectrometry; Pathomechanism; Proteomics

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN; COLLAGEN ALPHA1 CHAIN; IFOSFAMIDE; OSTEOPONTIN; PROTEINASE; PROTEOME; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; AMINO ACID SEQUENCE; ARTICLE; CAPILLARY ELECTROPHORESIS; CHILD; CLINICAL ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; CYSTINOSIS; FANCONI RENOTUBULAR SYNDROME; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY TUBULE EXCRETION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MASS SPECTROMETRY; MEMBRANOUS GLOMERULONEPHRITIS; MOLECULAR WEIGHT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; TUBULAR DYSFUNCTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FANCONI SYNDROME; FEMALE; HUMANS; MALE; PROTEOME;

EID: 67651114065     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp063     Document Type: Article

References (42)

1. Bakx CJ. Renal rickets, renal diabetes and cystine metabolism; the De Toni-Fanconi-Debre syndrome. Ned Tijdschr Geneeskd 1950; 94: 2326-2335
2. Van'T Hoff WG. Molecular developments in renal tubulopathies. Arch Dis Child 2000; 83: 189-191
3. Lee S, Lee T, Lee B et al. Fanconi's syndrome and subsequent progressive renal failure caused by a Chinese herb containing aristolochic acid. Nephrology (Carlton) 2004; 9: 126-129
4. Watanabe T, Yoshikawa H, Yamazaki S et al. Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol 2005; 20: 814-817
5. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006; 2: 80-91
6. Izzedine H, Launay-Vacher V, Isnard-Bagnis C et al. Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003; 41: 292-309
7. Christensen EI, Gburek J. Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology. Pediatr Nephrol 2004; 19: 714-721
8. Decramer S, Gonzalez de Peredo A, Breuil B et al. Urine in clinical proteomics. Mol Cell Proteomics 2008; 7: 1850-1862
9. Vilasi A, Cutillas PR, Maher AD et al. Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome. Am J Physiol Renal Physiol 2007; 293: F456-F467
10. Mischak H, Apweiler R, Banks RE et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. PROTEOMICS - Clin Appl 2007; 1: 148-156
11. Haubitz M, Wittke S, Weissinger EM et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005; 67: 2313-2320
12. Rossing K, Mischak H, Dakna M et al. Proteomic discovery and validation of urinary biomarkers for diabetes and chronic renal disease. J Am Soc Nephrol 2008; 19: 1283-1290
13. Julian BA, Wittke S, Novak J et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007; 28: 4469-4483
14. Thongboonkerd V. Practical points in urinary proteomics. J Proteome Res 2007; 6: 3881-3890
15. Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006; 7: 230-240
16. Kolch W, Neususs C, Pelzing M et al. Capillary electrophoresis- mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005; 24: 959-977
17. Neuhoff N, Kaiser T, Wittke S et al. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface- enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 149-156
18. Theodorescu D, Fliser D, Wittke S et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005; 26: 2797-2808
19. Jantos-Siwy Schiffer E, Brand K, Schumann G et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2008; 8: 268-281
20. Decramer S, Wittke S, Mischak H et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006; 12: 398-400
21. DeLeo JM. Receiver operating characteristic laboratory (ROCLAB): software for developing decision strategies that account for uncertainty. Second International Symposium on Uncertainty Modeling and Analysis. IEEE Computer Society Press, College Park, MD, USA 1993; 318-325
22. Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment. New York: Wiley, 1993
23. Dudoit S, Van Der Laan MJ. Multiple Testing Procedures and Applications to Genomics. Berlin: Springer, 2007
24. Zurbig P, Renfrow MB, Schiffer E et al. Biomarker discovery by CEMS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006; 27: 2111-2125
25. Coon JJ, Shabanowitz J, Hunt DF et al. Electron transfer dissociation of peptide anions. J Am Soc Mass Spectrom 2005; 16: 880-882
26. Good DM, Coon JJ. Advancing proteomics with ion/ion chemistry. Biotechniques 2006; 40: 783-789
27. Syka JE, Coon JJ, Schroeder MJ et al. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci USA 2004; 101: 9528-9533
28. Good DM, Wirtala M, McAlister GC et al. Performance characteristics of electron transfer dissociation mass spectrometry. Mol Cell Proteomics 2007; 6: 1942-1951
29. Lun A, Suslovych M, Drube J et al. Reliability of different expert systems for profiling proteinuria in children with kidney diseases. Pediatr Nephrol 2008; 23: 285-290
30. Cutillas PR, Chalkley RJ, Hansen KC et al. The urinary proteome in Fanconi syndrome implies specificity in the reabsorption of proteins by renal proximal tubule cells. Am J Physiol Renal Physiol 2004; 287: 353-364
31. Gaudin-Audrain C, Gallois Y, Pascaretti-Grizon F et al. Osteopontin is histochemically detected by the AgNOR acid-silver staining. Histol Histopathol 2008; 23: 469-478
32. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 1999; 10: 2323-2331
33. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 2007; 102: 912-924
34. Verkoelen CF, Verhulst A. Proposed mechanisms in renal tubular crystal retention. Kidney Int 2007; 72: 13-18
35. Saemann MD, Weichhart T, Hörl WH et al. Tamm-Horsfall protein: a multilayered defence molecule against urinary tract infection. Eur J Clin Invest 2005; 35: 227-235
36. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784
37. Haffner D, Weinfurth A, Manz F et al. Long-term outcome of paediatric patients with hereditary tubular disorders. Nephron 1999; 83: 250-260
38. Rossi R, Ehrich JHH. Partial and complete de Toni-Debré-Fanconi syndrome after ifosfamide chemotherapy of childhood malignancy. Eur J Clin Pharmacol 1993; 44: 43-45
39. Skinner R, Cotterill SJ, Stevens MCG. United Kingdom Children's Cancer Study Group. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. Br J Cancer 2000; 82: 1636-1645
40. Caron HN, Abeling N, van Gennip A et al. Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Med Pediatr Oncol 1992; 20: 42-47
41. Rossi R. Nephrotoxicity of ifosfamide - moving towards understanding the molecular mechanisms. Nephrol Dial Transplant 1997; 12: 1091-1092
42. Church DN, Hassan AB, Harper SJ et al. Osteomalacia as a late metabolic complication of ifosfamide chemotherapy in young adults: illustrative cases and review of the literature. Sarcoma 2007; Article ID: 91586